iSERA Lifesciences Ltd (534920)
🎯 Key Takeaways
- iSERA Lifesciences Ltd appears to be in a highly volatile and potentially distressed phase, marked by prolonged losses, negative ROE, and erratic financial performance over multiple years. The company has not demonstrated consistent operational or financial recovery, with management showing no clear turnaround narrative in recent filings.
- Revenue declined 69.3% QoQ to ₹1 in Q1FY20.
- ⚠️ Persistent operational underperformance with declining revenue and no profitability over multiple years.
📖 The Story
iSERA Lifesciences Ltd appears to be in a highly volatile and potentially distressed phase, marked by prolonged losses, negative ROE, and erratic financial performance over multiple years. The company has not demonstrated consistent operational or financial recovery, with management showing no clear turnaround narrative in recent filings. The stock's extraordinary 1Y return (+2506.88%) likely reflects extreme price volatility or corporate actions rather than fundamental improvement.
📰 What's Happening
The most recent quarterly results (June 2019) show negligible revenue (₹1 crore) and operating losses, consistent with earlier periods of minimal commercial activity. Earlier filings indicate a sharp decline in promoter stake from 91.1% in Q3FY26 to 58.63% by Q4FY26, suggesting possible dilution or promoter disengagement. Despite this, there has been no public announcement of strategic restructuring, new product launches, or major contracts in recent filings. The company has not provided forward guidance or discussed business revival plans in its latest disclosures.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 |
|---|---|---|---|---|
| Revenue | 10 | 4 | 4 | 1 |
| Operating Profit | 0 | 0 | 0 | -0 |
| OPM % | 0.7% | 1.9% | 3.3% | -0.9% |
| Net Profit | 0 | -0 | -0 | -0 |
| EPS | ₹0.02 | ₹-0.01 | ₹-0.03 | ₹-0.06 |
Revenue has declined significantly over the past several years, from ₹10 crore in June 2018 to just ₹1 crore in June 2019, with operating margins remaining near zero or negative. This downward trend contradicts any notion of scaling or profitability, and the company continues to report minimal net income and negative EPS. The financial trajectory reflects stagnation or erosion of operations, with no visible catalysts for improvement in the near term.
🔮 Management Outlook & What's Next
There is no available forward guidance or explicit outlook from management in the latest filings. Management has not provided any commentary on future revenue expectations, margins, or strategic direction in the recent quarterly results or annual reports. The absence of guidance suggests either uncertainty or a lack of a defined roadmap for recovery.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 |
| Reserves | 3 | 4 | -10 | -10 |
| Borrowings | 6 | 2 | 10 | 11 |
| Total Liabilities | 25 | 25 | 20 | 18 |
| Fixed Assets | 3 | 4 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 25 | 25 | 20 | 18 |
The balance sheet shows stable but minimal equity of ₹11 crore over multiple years, with persistent negative reserves indicating accumulated losses. Borrowings have slightly increased, but the company maintains negligible asset levels, suggesting limited capital investment or operational scale. There is no evidence of aggressive deleveraging or capital return initiatives, implying a conservative or passive capital approach amid weak operations.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2019 |
|---|---|
| Operating | -0 |
| Investing | -0 |
| Financing | +1 |
| Net Cash Flow | +0 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 3.6% | 58.6% | 58.6% |
| FII | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% |
| Public | 91.1% | 35.7% | 35.4% |
| # Shareholders | 1,034 | 1,029 | 1,014 |
Promoter holding has declined sharply from 3.57% in Q3FY26 to 58.63% by Q4FY26, but this appears to reflect a prior extreme dilution event rather than ongoing selling. The current 58.63% promoter stake is stable, with no significant FII or DII participation. The large public float (35.4%) and 1,014 shareholders suggest retail dominance, but lack of institutional interest may signal skepticism about the company’s fundamentals.
⚖️ Peer Comparison — IT - Software
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| TCS | 8.56 L Cr | 17.2 | 63.2% | 46.7% | 0.00 |
| INFY | 4.68 L Cr | 15.6 | 44.9% | 32.7% | 0.00 |
| HCLTECH | 3.67 L Cr | 21.0 | 31.6% | 23.2% | 0.00 |
| WIPRO | 1.80 L Cr | 14.4 | 18.1% | 15.1% | 0.19 |
| TECHM | 1.60 L Cr | 28.2 | 24.8% | 17.4% | 0.00 |
| LTM | 1.37 L Cr | 26.1 | 30.5% | 21.6% | 0.00 |
| OFSS | 1.06 L Cr | 30.9 | 60.3% | 43.6% | 0.00 |
| PERSISTENT | 91,416 | 47.0 | 32.7% | 24.5% | 0.00 |
| COFORGE | 87,786 | 40.3 | 25.6% | 20.7% | 0.04 |
| MPHASIS | 47,828 | 25.0 | 22.3% | 17.8% | 0.17 |
⚠️ Risk Factors
1. Persistent operational underperformance with declining revenue and no profitability over multiple years. 2. Severe lack of transparency or strategic communication from management, including absence of forward-looking statements. 3. High share price volatility disconnected from fundamentals, raising concerns about speculative manipulation. 4. Minimal institutional or foreign investor interest, indicating low confidence in the business model.
🧠 Analyst's Read
iSERA Lifesciences remains a highly speculative entity with no clear evidence of operational revival or sustainable business momentum. Investors should monitor for any meaningful strategic shift, revenue visibility, or management communication, but current indicators suggest limited near-term upside potential.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd